These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

935 related articles for article (PubMed ID: 24528684)

  • 1. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
    Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
    Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
    Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
    Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
    Græsdal A; Bogsrud MP; Holven KB; Nenseter MS; Narverud I; Langslet G; Brekke M; Retterstøl K; Arnesen KE; Ose L
    J Clin Lipidol; 2012; 6(4):331-9. PubMed ID: 22836070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
    Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P
    J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity.
    Foody JM; Vishwanath R
    J Clin Lipidol; 2016; 10(4):970-986. PubMed ID: 27578130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein apheresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.
    Vogt A; Parhofer KG
    Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
    Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
    J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.
    D'Erasmo L; Gallo A; Cefalù AB; Di Costanzo A; Saheb S; Giammanco A; Averna M; Buonaiuto A; Iannuzzo G; Fortunato G; Puja A; Montalcini T; Pavanello C; Calabresi L; Vigna GB; Bucci M; Bonomo K; Nota F; Sampietro T; Sbrana F; Suppressa P; Sabbà C; Fimiani F; Cesaro A; Calabrò P; Palmisano S; D'Addato S; Pisciotta L; Bertolini S; Bittar R; Kalmykova O; Béliard S; Carrié A; Arca M; Bruckert E
    Orphanet J Rare Dis; 2021 Sep; 16(1):381. PubMed ID: 34496902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.
    Santos RD; Stein EA; Hovingh GK; Blom DJ; Soran H; Watts GF; López JAG; Bray S; Kurtz CE; Hamer AW; Raal FJ
    J Am Coll Cardiol; 2020 Feb; 75(6):565-574. PubMed ID: 32057369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies].
    Zambon A
    G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):22S-30. PubMed ID: 27312020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.